Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
|Articles|November 1, 2013
- Applied Clinical Trials-11-01-2013
- Volume 22
- Issue 11
Cost Per Visit Trends Higher for Less Established Regions
IMS Health
Advertisement
Many factors affect a sponsor's decision to pick a region in which to conduct a clinical trial. Clinical grant expenditures represent a significant portion of later phase clinical trial budgets. Therefore, the relative cost per visit can play a large role in which region to select.
Figure 1. Cost per visit rate trends, 2008-2010 and 2011-2013.
IMS Health's current analysis demonstrates that the cost per patient visit in the newer, emerging geographies, is growing more rapidly than in more established regions. The established regions (Western Europe, US/Canada, and Australia/New Zealand) have been averaging 8% annual increases from 2011-2013, while grant costs in developing regions (East Asia, Latin America, and Eastern Europe) are growing at two to three times those rates with an average of 23%. Even if these emerging regions are starting off on a lower base as compared to well established regions, the rapid rise in cost in these regions warrant careful consideration in the coming years.
—IMS Health (for more information contact
Articles in this issue
about 13 years ago
Sponsors Struggle with Data Disclosure Requirementsabout 13 years ago
Evaluation of Data for Multi-Regional Trials: A Three-Layer Approachabout 13 years ago
Modeling Successful Phase III Trialsabout 13 years ago
GCP's Future: Looking Ahead to the Next 20 Yearsabout 13 years ago
Crunch-Time for Europe's Clinical Trials Rulesabout 13 years ago
Device Independence is the Future of Clinical Trialsabout 13 years ago
Business and People November 2013about 13 years ago
Adoption of Adaptive Trial Designs Poised to Accelerateabout 13 years ago
Applied Clinical Trials Digital Edition - November 2013Advertisement
Related to this article
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Embedding AI Across Operations, Faster Trial Decisions, and Voceryq Approval
5